Lauric acid leelamide is the lauric (C-12) amide analog of leelamine. Leelamine has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, exhibiting 20% displacement of [3H]-CP55940 at a concentration of 10 µM.1 Leelamine inhibits pyruvate dehydrogenase kinase (PDK) with an IC50 value of 9.5 µM.2 Derivatives of leelamine exhibit anti-inflammatory activity and show moderate inhibition of phospholipase A2 activity from a variety of sources.3 There are no published studies of the pharmacological properties of lauric acid leelamide.
1
Martin, B.R. Leelamine. (2006 Apr 27).
2
Aicher, T.D., Damon, R.E., Koletar, J., et al. Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK). Bioorg Med Chem Lett92223-2228(1999).
3
Wilkerson, W., DeLucca, I., Galbraith, W., et al. Antiinflammatory phospholipase-A2 inhibitors. I. Eur J Med Chem26667-676(1991).